Amarantus' ADHD drug performs well in Phase IIa study


Amarantus Bioscience's (AMBS) Eltoprazine treatment for adults with ADHD met its primary target in a Phase IIa trial of 47 patients and demonstrated 25% greater efficacy vs a placebo.

No serious adverse events took place, while most of the side effects were "mild of moderate." Still, only 36 subjects completed the study.

Amarantus is reviewing it options for the further advancement of its ADHD program, including business-development possibilities as the company prepares to up-list to a national stock exchange. (PR)

Comments (11)
  • positivethoughts
    , contributor
    Comments (2065) | Send Message
     
    25% improvement over placebo shouldnt qualify as proof of effectiveness. Especially considering ADHD testing is a a qualitative assessment.
    4 Feb 2014, 09:36 AM Reply Like
  • Chris Hofmann
    , contributor
    Comments (756) | Send Message
     
    It is statistically significant, which is all that matters. Like you said, it is a qualitative assessment, which means that lots of placebo patients will "think" they are getting better because they want to be getting better. It makes sense that both numbers might be artificially inflated by some degree. What is important is that:

     

    1. There is improvement.
    2. It is statistically significant.
    4 Feb 2014, 09:39 AM Reply Like
  • positivethoughts
    , contributor
    Comments (2065) | Send Message
     
    That is a very low threshold, considering doctors can force patients to take such drugs.
    4 Feb 2014, 09:41 AM Reply Like
  • Chris Hofmann
    , contributor
    Comments (756) | Send Message
     
    The better way to look at this would be to dig up the Adderall Phase 2a studies and see how it compared to the placebo. I have not done this.
    4 Feb 2014, 10:35 AM Reply Like
  • BuyToSell
    , contributor
    Comments (481) | Send Message
     
    The fact that it's measurable and there is an improvement means that they are on the right track. A lot of science is trial and error and rarely does it happen like in a movie, where they go from idea to completed product in one episode. The fact that there is measurable improvement gives them a positive development to work with and lets them know they are on the right track. Now they can work on refining and improving what they found and making it better, and then hopefully show greater efficacy in the next round of testing...
    4 Feb 2014, 10:19 AM Reply Like
  • BuyToSell
    , contributor
    Comments (481) | Send Message
     
    Keep in mind this is still only Phase IIa...
    4 Feb 2014, 10:19 AM Reply Like
  • uirapuru0
    , contributor
    Comment (1) | Send Message
     
    This study and resulting information is over four years old, why is it being revisited now?
    4 Feb 2014, 12:10 PM Reply Like
  • Alao
    , contributor
    Comments (8) | Send Message
     
    If that is the case then it looks like the PR machine is out in full force. I hope that is not the case. They need good PR not inflated old news
    4 Feb 2014, 03:33 PM Reply Like
  • BuyToSell
    , contributor
    Comments (481) | Send Message
     
    Do you have a link to information time stamped as old? I have received this information today not just through seeking Alpha but through my brokerage as well.
    4 Feb 2014, 03:46 PM Reply Like
  • Chris Hofmann
    , contributor
    Comments (756) | Send Message
     
    The drug is an older drug that they recently came into ownership of (in January 2014). They are clearly using the PRs to let people know why they like this drug and how they will be utilizing it going forward. Some of the reports are of course old since they have not yet run any new studies since they just received the drug.
    4 Feb 2014, 04:00 PM Reply Like
  • BuyToSell
    , contributor
    Comments (481) | Send Message
     
    Ah ok thanks Chris that explains why the news didn't really move the needle on the stock price.
    4 Feb 2014, 04:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs